Hypophosphatasia Treatment: Current Treatment Options for Hypophosphatasia
What is Hypophosphatasia?
Hypophosphatasia Treatment is a rare genetic disorder that impairs the body’s ability to mineralize bones. It is caused by mutations in the gene that codes for the enzyme alkaline phosphatase. This enzyme plays a critical role in bone mineralization by releasing inorganic pyrophosphate. Without sufficient alkaline phosphatase activity, bones cannot mineralize properly, leading to softened and weakened bones.
Symptoms of Hypophosphatasia
The signs and symptoms of hypophosphatasia vary depending on the age of onset and severity. In infants and children, severe forms are typically characterized by failure to thrive, poor feeding, respiratory problems, skeletal abnormalities, and seizures. Adults may experience bone pain, fractures, loss of mobility, and muscle weakness. Dental problems are common across all ages. Bones most commonly affected are the skull, ribs, legs, and pelvis.
Diagnosis and Testing
A diagnosis of hypophosphatasia is based on a combination of clinical observations, family history, physical examination, and lab tests. Tests that help confirm the diagnosis include alkaline phosphatase levels in blood (very low), urine for inorganic pyrophosphate (elevated), and genetic testing to identify mutations in the ALPL gene. Imaging tests like X-rays and MRIs show abnormalities and deformities in developing bones. The severity is classified based on age of onset and clinical signs.
Enzyme Replacement Therapy
As of now, the only approved treatment is enzyme replacement therapy (ERT) with asfotase alfa, sold under the brand name Strensiq. It is administered as a subcutaneous injection, typically 2-3 times per week. Asfotase alfa is a recombinant form of human tissue-nonspecific alkaline phosphatase that replaces the missing or defective enzyme in the body. Clinical trials have shown it to be effective at improving survival, healing fractures, developing skulls and long bones, and increasing mobility in infants and children with the severe forms of hypophosphatasia. It has also helped reduce bone pain and improve quality of life in adults.
While ERT has significantly improved outcomes, it does not cure the condition and lifelong treatment is required. It is also very expensive, costing over $500,000 per year. Not all patients see complete resolution of symptoms. The dosage and frequency may need adjustment based on response and monitoring of alkaline phosphatase levels and other factors. Overall, it has been a breakthrough that has transformed the disease trajectory for many patients. However, more affordable and widely accessible treatment options are still needed.
Other Hypophosphatasia Treatment Approaches
Besides ERT, management involves supportive measures to address specific symptoms and complications. Physical and occupational therapy helps improve muscle strength and mobility. Braces, casts and sometimes surgery may be needed for bone deformities and fractures. Vitamin and mineral supplements provide additional skeletal support. Pain medications are given as needed. In severe cases, ventilatory support or tracheostomy may be required. Dental care involving fillings, extractions or dentures addresses oral health issues. While not curative, a multidisciplinary approach can help maximize function and quality of life.
Future Hypophosphatasia Treatment Directions
Research is ongoing to develop more effective and affordable treatment options for hypophosphatasia. Second-generation enzyme therapies aim to enhance delivery, stability and efficacy compared to the current ERT. Gene therapy approaches involving recombinant vectors to deliver the healthy ALPL gene show promise in animal studies but need significant development for human use. Small molecule therapies are also under investigation as a potential oral alternative to intravenous ERT. They work by different mechanisms to boost alkaline phosphatase levels or activity. While still in early research phases, they could transform hypophosphatasia management if successful. Improved understanding of disease mechanisms at the molecular level continues to spur new therapeutic discoveries and clinical trials. This gives hope that future patients may have better options.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
